Seres Therapeutics, Inc. (MCRB)
After hours:
| Previous close | 1.0600 |
| Open | 1.0900 |
| Bid | 1.0600 x 3000 |
| Ask | 1.1200 x 3000 |
| Day's range | 1.0411 - 1.1450 |
| 52-week range | 0.9100 - 6.8700 |
| Volume | |
| Avg. volume | 3,553,320 |
| Market cap | 139.598M |
| Beta (5Y monthly) | 2.49 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.1100 |
| Earnings date | 05 Mar 2024 - 11 Mar 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.25 |
Simply Wall St.Seres Therapeutics, Inc. (NASDAQ:MCRB) is a favorite amongst institutional investors who own 62%
Key Insights Given the large stake in the stock by institutions, Seres Therapeutics' stock price might be vulnerable to...
- Business Wire
Seres Therapeutics to Participate in the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023; Webcast at 3:30 p.m. ET
CAMBRIDGE, Mass., November 28, 2023--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Seres management will participate at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 3:30 p.m. ET.
PR NewswireFlagship Pioneering Unveils Quotient Therapeutics to Create Transformative Medicines Informed by a New Frontier of Genetics
Flagship Pioneering, the bioplatform innovation company, today unveiled Quotient Therapeutics, a company pioneering somatic genomics, the study of genetic variation at the cellular level, to discover therapeutics informed by new links between genes and disease. Flagship has made an initial commitment of $50 million to advance development of the company's platform following two years of development at Flagship Labs and pursue a pipeline of medicines across a wide range of therapeutic areas and mo
